Dung T. Le

Research interests

Publications

• Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00197-8

• Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2017699

• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.02107

• Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

  Science · 2019 · 10.1126/science.aau0447

• Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.02105

• CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.76.6212

• DNA mismatch repair in cancer

  Pharmacology & Therapeutics · 2018 · 10.1016/j.pharmthera.2018.04.004

• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  Science · 2017 · https://doi.org/10.1126/science.aan6733

• Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.68.3672

• Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

  Cancer Discovery · 2016 · 10.1158/2159-8290.cd-16-1223

• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30098-5

• Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)00175-3

• Microsatellite Instability as a Biomarker for PD-1 Blockade

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-15-1678

• Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30496-x

• Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

  Kidney International · 2016 · 10.1016/j.kint.2016.04.008

• Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

  Annals of the Rheumatic Diseases · 2016 · 10.1136/annrheumdis-2016-209595

• Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.57.4244

• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1500596

• PD-1 blockade in tumors with mismatch repair deficiency.

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.33.15_suppl.lba100

• Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

  Science Translational Medicine · 2014 · 10.1126/scitranslmed.3007094

• Evolutionary dynamics of cancer in response to targeted combination therapy

  eLife · 2013 · 10.7554/elife.00747

• Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

  Journal of Immunotherapy · 2013 · 10.1097/cji.0b013e31829fb7a2

• A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-11-2121

• A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

  Annals of Surgery · 2011 · 10.1097/sla.0b013e3181fd271c

• Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation

  Clinical Cancer Research · 2008 · 10.1158/1078-0432.ccr-07-0371

Current projects

No projects listed.